I-Autoinjector engaphansi kwe-Weekly Subcutaneous
I-Rasuvo (methotrexate), i-autoinjector ene-single-dose ene-prescription drug methotrexate , yamukelwa yi-US Food and Drug Administration (FDA) ngoJulayi 11, 2014. I-Rasuvo, eyenziwe nguMedac, Pharma, Inc. ilula- sebenzisa okunye okunye kumethotrexate ngomlomo noma ifomu elijova nge-vial-and-syringe.
Izinkomba zikaRasuvo
I-Rasuvo ivunyelwe ukuphathwa kweziguli ezine- arthritis enamandla, esebenzayo ye- rheumatoid arthritis kanye ne- polyarticular yezingane ezincane ze-idiopathic arthritis ezingenakho ukuphendula ngokwanele kumuthi wokuqala we-line noma ezingenakubekezela.
I-Rasuvo iboniswa futhi ekulawuleni izimpawu ezihlobene nokuhlukumezeka okukhulu, ukuvuselela, ukukhubaza i-psoriasis kubantu abadala abahluleka ukuthola impendulo eyanelisayo nezinye izinketho zokwelapha. ( Qaphela: Rasuvo akufanele isetshenziselwe ukwelapha izifo ezithathelwanayo.)
Ukuphathwa kweRasuvo
I-Rasuvo ilawulwa kanye ngesonto nje njengemjovo engaphansi kokuphela. I-Rasuvo itholakala ngamandla ayisilinganiso angu-10 kusuka ku-7.5 mg ukuya ku-30 mg (ku-2.5 mg ukunyuka). I-autoinjector ibangelwa ngesandla futhi kufanele ijowe esiswini noma ithanga. Amanye ama-methotrexate kufanele asetshenziswe uma ngabe umthamo ongaphansi kuka-7.5 mg noma ngaphezulu kuka-30 mg umisiwe-noma uma ukulungiswa okungaphansi kuka 2.5 mg kuyadingeka.
Umthamo wokuqala we-methotrexate we-arthritis ye-rheumatoid ingu-7.5 mg kanye ngesonto ngomjovo womlomo noma ongaphansi komzimba. I-psoriasis, isilinganiso esivamile sokuqala umthamo ngu-10-25 mg kanye ngesonto nge-oral oral, intramuscular, subcutaneous, noma intravenous administration.
Ku-arthritis ye-polyarticular ye-idiopathic arthritis, isilinganiso sokuqala singama-10mg / m2 kanye ngesonto ngalinye (m2 iyi-metre square yomzimba womhlaba).
Ubani Ongayisebenzisi Rasuvo?
Iziguli ze-rheumatoid arthritis ezikhulelwe akufanele zisebenzise i-Rasuvo. Kumelwe futhi kugwenywe ngamama ohlengikazi, kanye neziguli ezisebenzisayo: izidakamizwa noma izifo zesibindi, i-immunodeficiency syndromes, noma i-preexisting blood dyscrasias.
Iziguli ezine-hypersensitivity eyaziwa yi-methotrexate kufanele futhi zigweme u-Rasuvo.
Ukusabela Okubi Okuvamile
Kukhona ukusabela okubi okuvamile okuhambisana noRasuvo kufaka phakathi, ukuhlukunyezwa, ubuhlungu besisu, i-dyspepsia, isisu noma izilonda zomlomo, i-nasopharyngitis, isifo sohudo, ukuhlolwa kwesibindi, ukuhlanza, ikhanda, i-bronchitis, amaplatelet aphansi), i-alopecia, i-leukopenia (i-white white cell cell ukubalwa), i-pancytopenia (ukubalwa okuphansi kwazo zonke izinhlobo zamaseli egazi), isizungu, nokuzwela ekukhanyeni kwe-ultraviolet. Uma unempendulo engalungile, ungayibika kumkhiqizi wezidakamizwa ku-1-855-336-3322, ku-FDA ku-1-800-FDA-1088, noma ku-Medwatch ku-http: //www.fda.gov/medwatch .
Ukusebenzisana kwezidakamizwa
Udokotela wakho kufanele abe nohlu lwazo zonke izidakamizwa kanye nezithako ozithathe manje. Qaphela ukuthi ngokuthatha i-aspirin, i- NSAID , noma imithi ye- corticosteroid kanye no-Rasuvo, amazinga we-serum methotrexate angase ahlale isikhathi eside (okungukuthi, angase ahlale egazini lakho isikhathi eside) futhi angase akhulise ingozi yobuthi.
Ukuthatha i-proton pump inhibitors (isb., I-Nexium noma i-omeprazole) no-Rasuvo nakho kungandisa isikhathi se-serum methotrexate futhi kwandise ingozi yobuthi.
Ukuxwayiswa nokuqapha
I-Rasuvo ifaka isixwayiso se-Boxed (uhlobo olubi kakhulu lwesixwayiso esikhishwe).
Amaphuzu avelele e-Boxed Warning yi:
- I-Rasuvo kufanele isetshenziswe kuphela odokotela ngolwazi nangolwazi lwe-antimetabolite therapy. I-Rasuvo iyi-inhibitor ye-analog ye-analog.
- Ngenxa yokuthi kungenzeka ukuthi isifo esibi kakhulu, okungenzeka sibulawe, uRasuvo kufanele inqunywe kuphela kulabo abane-arthritis ye-rheumatoid, i-psoriasis, noma i-polyarticular ye-arthritis ye-idiopathic yezingane ezingaphenduli kwezinye izifo.
- I-Methotrexate ibike ukuthi ibangele ukufa komntwana noma ukungazalwa komzimba.
- Ukuqedwa kwe-Methotrexate kunciphise kulabo abanenkinga yokukhubazeka kwezinso, ama-ascites, noma ama-pleusion effusion.
- Ukuncipha komnumongo we-bone, i-anemia ye-aplastic, kanye ne-toxicity yomzimba kungenzeka ngokungalindelekile futhi kungabulala uma i-methotrexate ithathwa ngama-NSAID.
- Ukusetshenziswa isikhathi eside kwe-methotrexate kungabangela i-hepatotoxicity, fibrosis, ne-cirrhosis. Izivivinyo ze-biopsy zesibindi zingaboniswa.
- Izifo zamaphaphu ezenziwe ngamatrotrexate (isb., I-pneumonitis ephakathi nendawo engapheli) ingenzeka, ngisho nangamanani aphansi.
- Isifo sohudo kanye nesifo se-ulcerative sidinga ukuthi ukwelashwa nge-methotrexate kumiswe ukuvimbela ukuphazamiseka kwamathumbu emathunjini noma ukungena kwamagciwane.
- I-malignant lymphoma ingase ikhule ngisho ne-methotrexate yesilinganiso esincane. Isidakamizwa kufanele siphenduke ukuze sibone ukuthi i-lymphoma igxila yini.
- I-Methotrexate ingadala "i-tumor lysis syndrome" ezigulini ezinezikhumba ezikhula ngokushesha.
- Ukushisa okukhulu, ngezinye izikhathi kubulalayo, isikhumba singenzeka ngokusetshenziswa kwe-methotrexate.
- Kungenzeka ukuthi izifo ezithathelanayo ezibulalayo zingase zenzeke nge-methotrexate ukusetshenziswa.
- Uma i-methotrexate inikezwa kanye ne-radiotherapy, kungase kube khona ingozi yokwanda kwezicubu ze-necrosis ne- osteonecrosis .
Okubalulekile
I-Rasuvo yindlela elula yokwakhiwa kwe-methotrexate. I-Rasuvo ithwala yonke imiphumela engaba yingozi kanye nezixwayiso ezixhunyiwe ezihlotshaniswa nezinye izinqubo ze-methotrexate.
Imithombo
Rasuvo. Ulwazi lokuPhelela okugcwele . Kubuyekezwe i-7/2014.
Umlando Wokugunyaza we-Rasuvo. drug.com.